SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2024-06-27** | Period of Report: **2024-06-23**
SEC Accession No. 0001193125-24-169795

([HTML Version](#) on secdatabase.com)

FILER

Bellevue Life Sciences Acquisition Corp. CIK:**1840425**| IRS No.: **845052822** | State of Incorp.:**DE** | Fiscal Year End: **1231** Type: **8-K** | Act: **34** | File No.: **001-41390** | Film No.: **241075479** SIC: **3841** Surgical & medical instruments & apparatus	Mailing Address *10900 NE 4TH STREET,* *SUITE 2300* *BELLEVUE WA 98004*	Business Address *10900 NE 4TH STREET,* *SUITE 2300* *BELLEVUE WA 98004* *425-635-7700*

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.
(Exact Name of Registrant as Specified in Charter)

Delaware	**001-41390**	**84-5052822**
(State or Other Jurisdiction	**(Commission**	**(IRS Employer**
of Incorporation)	**File Number)**	**Identification No.)**

10900 NE 4th Street, Suite 2300, Bellevue, WA	**98004**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's telephone number, including area code (425) 635-7700

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of common stock, one redeemable warrant and one right	BLACU	The Nasdaq Stock Market LLC
Common stock, par value $0.0001 per share	BLAC	The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share	BLACW	The Nasdaq Stock Market LLC
Right to receive one-tenth (1/10) of one share of common stock	BLACR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.   **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers**

On June 23, 2024, the Board of Directors (the "Board") of Bellevue Life Sciences Acquisition Corp. (the "Company") appointed Mr. Sang Hyun Kim as a director, effective immediately. Mr. Kim was appointed as a member of the Audit Committee of the BLAC Board (the "Audit Committee"), filling the vacancy created by the resignation of Inchul Chung, as previously reported by BLAC on Form 8-K filed with the SEC on June 13, 2024 (the "June 13 Form 8-K"). Additionally, Mr. Kim was appointed as a member of the Compensation Committee of the BLAC Board ("the Compensation Committee") and a member of the M&A Committee, filling vacancies created by the resignation of Mr. Radclyffe Roberts as previously reported on the June 13 Form 8-K.

Mr. Kim, 53, currently serves as the Special Advisor of Marketing, Private Equity Funds at Korea Daesung Asset Management Co., Ltd. the position held by him since January 2021. Prior to that, Mr. Kim has spent approximately 11 years working in different positions with Samsung Group including, most recently, as part of the Global M&A Strategy Team at Samsung Asset Management HQ from January 2020 to December 2020. He also served as CEO, Regional Managing Director at Samsung Asset Management Beijing Ltd. from October 2016 to December 2019, Chief Strategy Officer & Global Business Development Officer at Samsung Asset Management HQ from April 2013 to September 2016, and Senior Principal, Corporate Planning and Strategy Department at Samsung Fire and Marine Insurance from January 2010 to March 2013. Mr. Kim earned his MBA degree from Georgetown University in 2001, and his M.A. (Public Policy) and B.S. (International Economics) from Seoul National University. BLAC believes Mr. Kim is well qualified to serve as a director because of his extensive experience in both legal and investment sectors across various asset classes, demonstrating significant expertise in capital markets.

The BLAC Board has affirmatively determined that Mr. Kim meets the applicable standards for an independent director under the rules of the Nasdaq Stock Market LLC. Mr. Kim will not be compensated by BLAC for his services as a director. In connection with his appointment, Mr. Kim has entered into a Letter Agreement and an Indemnity Agreement with BLAC on the same terms as the Letter Agreement and Indemnity Agreement entered into by the directors and officers of BLAC at the time of the BLAC's initial public offering and in the form previously filed as Exhibits 10.1 and 10.6, respectively, to BLAC's Annual Report on Form 10-K filed with the SEC on April 17, 2024.

Other than the foregoing, Mr. Kim is not a party to any arrangement or understanding with any person pursuant to which he was appointed as director, nor is he party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving BLAC.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 27, 2024

<div align="right">

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: /s/ Kuk Hyoun Hwang

Name: Kuk Hyoun Hwang
Title: Chief Executive Officer

</div>

Document And Entity Information [Line Items]

Amendment Flag	false
Entity Central Index Key	0001840425
Document Type	8-K
Document Period End Date	Jun. 23, 2024
Entity Registrant Name	BELLEVUE LIFE SCIENCES ACQUISITION CORP.
Entity Incorporation State Country Code	DE
Entity File Number	001-41390
Entity Tax Identification Number	84-5052822
Entity Address, Address Line One	10900 NE 4th Street
Entity Address, Address Line Two	Suite 2300
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(425)
Local Phone Number	635-7700
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]

Document And Entity Information [Line Items]

Security 12b Title	Units, each consisting of one share of common stock, one redeemable warrant and one right
Trading Symbol	BLACU
Security Exchange Name	NASDAQ

Common Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title	Common stock, par value $0.0001 per share
Trading Symbol	BLAC
Security Exchange Name	NASDAQ

Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]

Document And Entity Information [Line Items]

Security 12b Title	Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share
Trading Symbol	BLACW

[Security Exchange Name](#) NASDAQ

[Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]](#)

[Document And Entity Information [Line Items]](#)

[Security 12b Title](#) Right to receive one-tenth (1/10) of one share of common stock

[Trading Symbol](#) BLACR

[Security Exchange Name](#) NASDAQ

```json
{
  "version": "2.2",
  "instance": {
    "d835518d8k.htm": {
      "nsprefix": "blacu",
      "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240623",
      "dts": {
        "schema": {
          "local": [
            "blacu-20240623.xsd"
          ],
          "remote": [
            "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
            "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
            "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
            "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
            "http://www.xbrl.org/2005/xbrldt-2005.xsd",
            "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
            "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
            "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
            "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
            "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
            "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
            "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
            "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
            "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
            "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
            "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
            "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
            "https://xbrl.sec.gov/country/2023/country-2023.xsd",
            "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
            "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
          ]
        },
        "definitionLink": {
          "local": [
            "blacu-20240623_def.xml"
          ]
        },
        "labelLink": {
          "local": [
            "blacu-20240623_lab.xml"
          ]
        },
        "presentationLink": {
          "local": [
            "blacu-20240623_pre.xml"
          ]
        },
        "inline": {
          "local": [
            "d835518d8k.htm"
          ]
        }
      },
      "keyStandard": 24,
      "keyCustom": 0,
      "axisStandard": 1,
      "axisCustom": 0,
      "memberStandard": 1,
      "memberCustom": 3,
      "hidden": {
        "total": 2,
        "http://xbrl.sec.gov/dei/2023": 2
      },
      "contextCount": 5,
      "entityCount": 1,
      "segmentCount": 4,
      "elementCount": 33,
      "unitCount": 0,
      "baseTaxonomies": {
        "http://xbrl.sec.gov/dei/2023": 33
      },
      "report": {
        "R1": {
          "role": "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation",
          "longName": "100000 - Document - Document and Entity Information",
          "shortName": "Document and Entity Information",
          "isDefault": "true",
          "groupType": "document",
          "subGroupType": "",
          "menuCat": "Cover",
          "order": "1",
          "firstAnchor": {
            "contextRef": "duration_2024-06-23_to_2024-06-23",
            "name": "dei:DocumentType",
            "unitRef": null,
            "xsiNil": "false",
            "lang": "en-US",
            "decimals": null,
            "ancestors": [
              "p",
              "div",
              "div",
              "body",
              "html"
            ],
            "reportCount": 1,
            "baseRef": "d835518d8k.htm",
            "first": true,
            "unique": true
          },
          "uniqueAnchor": {
            "contextRef": "duration_2024-06-23_to_2024-06-23",
            "name": "dei:DocumentType",
            "unitRef": null,
            "xsiNil": "false",
            "lang": "en-US",
            "decimals": null,
            "ancestors": [
              "p",
              "div",
              "div",
              "body",
              "html"
            ],
            "reportCount": 1,
            "baseRef": "d835518d8k.htm",
            "first": true,
            "unique": true
          }
        }
      },
      "tag": {
        "dei_AmendmentFlag": {
          "xbrltype": "booleanItemType",
          "nsuri": "http://xbrl.sec.gov/dei/2023",
          "localname": "AmendmentFlag",
          "presentation": [
            "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
          ],
          "lang": {
            "en-us": {
              "role": {
                "label": "Amendment Flag",
                "terseLabel": "Amendment Flag",
                "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
              }
            }
          },
          "auth_ref": []
        },
        "dei_CityAreaCode": {
          "xbrltype": "normalizedStringItemType",
          "nsuri": "http://xbrl.sec.gov/dei/2023",
          "localname": "CityAreaCode",
          "presentation": [
            "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
          ],
          "lang": {
            "en-us": {
              "role": {
                "label": "City Area Code",
                "terseLabel": "City Area Code",
                "documentation": "Area code of city"
              }
            }
          },
          "auth_ref": []
        },
        "us-gaap_ClassOfStockDomain": {
          "xbrltype": "domainItemType",
          "nsuri": "http://fasb.org/us-gaap/2023",
          "localname": "ClassOfStockDomain",
          "presentation": [
            "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
          ],
          "lang": {
            "en-us": {
              "role": {
                "label": "Class of Stock [Domain]",
                "terseLabel": "Class of Stock [Domain]"
              }
            }
          },
          "auth_ref": []
        },
        "us-gaap_CommonStockMember": {
          "xbrltype": "domainItemType",
          "nsuri": "http://fasb.org/us-gaap/2023",
          "localname": "CommonStockMember",
          "presentation": [
            "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
          ],
          "lang": {
            "en-us": {
              "role": {
                "label": "Common Stock [Member]",
                "terseLabel": "Common Stock [Member]"
              }
            }
          },
          "auth_ref": []
        },
        "dei_CoverAbstract": {
          "xbrltype": "stringItemType",
          "nsuri": "http://xbrl.sec.gov/dei/2023",
          "localname": "CoverAbstract",
          "lang": {
            "en-us": {
              "role": {
                "label": "Cover [Abstract]",
                "terseLabel": "Cover [Abstract]",
```

```
    "documentation": "Cover page."
   }
  }
 },
 "auth_ref": []
},
"blacu_DocumentAndEntityInformationLineItems": {
 "xbrltype": "stringItemType",
 "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240623",
 "localname": "DocumentAndEntityInformationLineItems",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Document And Entity Information [Line Items]",
    "terseLabel": "Document And Entity Information [Line Items]"
   }
  }
 },
 "auth_ref": []
},
"blacu_DocumentAndEntityInformationTable": {
 "xbrltype": "stringItemType",
 "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240623",
 "localname": "DocumentAndEntityInformationTable",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Document And Entity Information [Table]",
    "terseLabel": "Document And Entity Information [Table]"
   }
  }
 },
 "auth_ref": []
},
"dei_DocumentPeriodEndDate": {
 "xbrltype": "dateItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "DocumentPeriodEndDate",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Document Period End Date",
    "terseLabel": "Document Period End Date",
    "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
   }
  }
 },
 "auth_ref": []
},
"dei_DocumentType": {
 "xbrltype": "submissionTypeItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "DocumentType",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Document Type",
    "terseLabel": "Document Type",
    "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
   }
  }
 },
 "auth_ref": []
},
"dei_EntityAddressAddressLine1": {
 "xbrltype": "normalizedStringItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "EntityAddressAddressLine1",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Entity Address, Address Line One",
    "terseLabel": "Entity Address, Address Line One",
    "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
   }
  }
 },
 "auth_ref": []
},
"dei_EntityAddressAddressLine2": {
 "xbrltype": "normalizedStringItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "EntityAddressAddressLine2",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Entity Address, Address Line Two",
    "terseLabel": "Entity Address, Address Line Two",
    "documentation": "Address Line 2 such as Street or Suite number"
   }
  }
 },
 "auth_ref": []
},
"dei_EntityAddressCityOrTown": {
 "xbrltype": "normalizedStringItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "EntityAddressCityOrTown",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Entity Address, City or Town",
    "terseLabel": "Entity Address, City or Town",
    "documentation": "Name of the City or Town"
   }
  }
 },
 "auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
 "xbrltype": "normalizedStringItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "EntityAddressPostalZipCode",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Entity Address, Postal Zip Code",
    "terseLabel": "Entity Address, Postal Zip Code",
    "documentation": "Code for the postal or zip code"
   }
  }
 },
 "auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
 "xbrltype": "stateOrProvinceItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "EntityAddressStateOrProvince",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Entity Address, State or Province",
    "terseLabel": "Entity Address, State or Province",
    "documentation": "Name of the state or province."
   }
  }
 },
 "auth_ref": []
},
"dei_EntityCentralIndexKey": {
 "xbrltype": "centralIndexKeyItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "EntityCentralIndexKey",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Entity Central Index Key",
    "terseLabel": "Entity Central Index Key",
    "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
   }
  }
 },
 "auth_ref": [
  "r1"
 ]
},
"dei_EntityEmergingGrowthCompany": {
 "xbrltype": "booleanItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "EntityEmergingGrowthCompany",
 "presentation": [
  "http://BellevueLifeSciencesAcquisitionCorp.com/20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
 ],
 "lang": {
  "en-us": {
   "role": {
    "label": "Entity Emerging Growth Company",
    "terseLabel": "Entity Emerging Growth Company",
    "documentation": "Indicate if registrant meets the emerging growth company criteria."
   }
  }
 },
 "auth_ref": [
  "r1"
 ]
```

```
 },
 "dei_EntityExTransitionPeriod": {
  "xbrltype": "booleanItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "EntityExTransitionPeriod",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Entity Ex Transition Period",
     "terseLabel": "Entity Ex Transition Period",
     "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
    }
   }
  },
  "auth_ref": [
   "r7"
  ]
 },
 "dei_EntityFileNumber": {
  "xbrltype": "fileNumberItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "EntityFileNumber",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Entity File Number",
     "terseLabel": "Entity File Number",
     "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
    }
   }
  },
  "auth_ref": []
 },
 "dei_EntityIncorporationStateCountryCode": {
  "xbrltype": "edgarStateCountryItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "EntityIncorporationStateCountryCode",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Entity Incorporation State Country Code",
     "terseLabel": "Entity Incorporation State Country Code",
     "documentation": "Two-character EDGAR code representing the state or country of incorporation."
    }
   }
  },
  "auth_ref": []
 },
 "dei_EntityRegistrantName": {
  "xbrltype": "normalizedStringItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "EntityRegistrantName",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Entity Registrant Name",
     "terseLabel": "Entity Registrant Name",
     "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
    }
   }
  },
  "auth_ref": [
   "r1"
  ]
 },
 "dei_EntityTaxIdentificationNumber": {
  "xbrltype": "employerIdItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "EntityTaxIdentificationNumber",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Entity Tax Identification Number",
     "terseLabel": "Entity Tax Identification Number",
     "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
    }
   }
  },
  "auth_ref": [
   "r1"
  ]
 },
 "dei_LocalPhoneNumber": {
  "xbrltype": "normalizedStringItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "LocalPhoneNumber",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Local Phone Number",
     "terseLabel": "Local Phone Number",
     "documentation": "Local phone number for entity."
    }
   }
  },
  "auth_ref": []
 },
 "dei_PreCommencementIssuerTenderOffer": {
  "xbrltype": "booleanItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "PreCommencementIssuerTenderOffer",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Pre Commencement Issuer Tender Offer",
     "terseLabel": "Pre Commencement Issuer Tender Offer",
     "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
    }
   }
  },
  "auth_ref": [
   "r3"
  ]
 },
 "dei_PreCommencementTenderOffer": {
  "xbrltype": "booleanItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "PreCommencementTenderOffer",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Pre Commencement Tender Offer",
     "terseLabel": "Pre Commencement Tender Offer",
     "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
    }
   }
  },
  "auth_ref": [
   "r4"
  ]
 },
 "blacu_RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member": {
  "xbrltype": "domainItemType",
  "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240623",
  "localname": "RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]",
     "terseLabel": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]"
    }
   }
  },
  "auth_ref": []
 },
 "blacu_RightToReceiveOnetenth110OfOneShareOfCommonStockMember": {
  "xbrltype": "domainItemType",
  "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240623",
  "localname": "RightToReceiveOnetenth110OfOneShareOfCommonStockMember",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]",
     "terseLabel": "Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]"
    }
   }
  },
  "auth_ref": []
 },
 "dei_Security12bTitle": {
  "xbrltype": "securityTitleItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localname": "Security12bTitle",
  "presentation": [
   "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
  ],
  "lang": {
   "en-us": {
    "role": {
     "label": "Security 12b Title",
     "terseLabel": "Security 12b Title",
     "documentation": "Title of a 12(b) registered security."
    }
   }
  },
```

```json
    "auth_ref": [
     "r0"
    ]
   },
   "dei_SecurityExchangeName": {
    "xbrltype": "edgarExchangeCodeItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "SecurityExchangeName",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Security Exchange Name",
       "terseLabel": "Security Exchange Name",
       "documentation": "Name of the Exchange on which a security is registered."
      }
     }
    },
    "auth_ref": [
     "r2"
    ]
   },
   "dei_SolicitingMaterial": {
    "xbrltype": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "SolicitingMaterial",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Soliciting Material",
       "terseLabel": "Soliciting Material",
       "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
      }
     }
    },
    "auth_ref": [
     "r5"
    ]
   },
   "us-gaap_StatementClassOfStockAxis": {
    "xbrltype": "stringItemType",
    "nsuri": "http://fasb.org/us-gaap/2023",
    "localname": "StatementClassOfStockAxis",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Class of Stock [Axis]",
       "terseLabel": "Class of Stock [Axis]"
      }
     }
    },
    "auth_ref": []
   },
   "dei_TradingSymbol": {
    "xbrltype": "tradingSymbolItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "TradingSymbol",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Trading Symbol",
       "terseLabel": "Trading Symbol",
       "documentation": "Trading symbol of an instrument as listed on an exchange."
      }
     }
    },
    "auth_ref": []
   },
   "blacu_UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member": {
    "xbrltype": "domainItemType",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240623",
    "localname": "UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]",
       "terseLabel": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]"
      }
     }
    },
    "auth_ref": []
   },
   "dei_WrittenCommunications": {
    "xbrltype": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "WrittenCommunications",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240623/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Written Communications",
       "terseLabel": "Written Communications",
       "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
      }
     }
    },
    "auth_ref": [
     "r6"
    ]
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
```